Alterity Therapeutics Inc. (NASDAQ: ATHE) stock gained by 7.91% at last close whereas the ATHE stock price declines by 3.33% in the pre-market trading session. Alterity Therapeutics is a clinical-stage biotech firm devoted to a better future for those suffering from neurodegenerative disorders. ATH434 which is ATHE’s main asset, has the potential to treat a variety of Parkinson’s diseases.
>> 7 Top Picks for the Post-Pandemic Economy <<
What is happening?
The results of a research indicating that ATH434 decreases –synuclein associated neurodegeneration in a well-established mouse model of Multiple System Atrophy have been published in Movement Disorders, the authorized journal of the International Parkinson and Movement Disorder Society.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Read More
Professor Nadia Stefanova directed the research at the Facility for Translational Neurodegeneration Research, Department of Neurology, the Medical University of Innsbruck in Austria, a leading animal research laboratory in MSA
The preclinical investigation found that ATH434 therapy enhanced motor function and was neuroprotective, fully supporting and expanding prior findings from another university lab, together in the same MSA model and in animal models of Parkinson’s disease. ATH434 decreased both the accumulated form of –synuclein and the so-called toxic oligomeric form in preserved neurons, which is considered to be the cause of illness propagating to other neurons. ATH434 also decreased brain iron in regions of disease, which is consistent with its mode of action.
Furthermore,
Aside from these findings, the study also demonstrated for the first time that ATH434 maintained neurons in the striatum, a brain area known to be damaged in MSA patients. Importantly, ATH434 enhanced performance on a variety of motor tests, including a favorable effect on the balance-testing “challenging beam” task. This last result is particularly important for MSA patients, as the poor balance is a primary source of impairment.
